Long-Term Safety and Efficacy of Janus kinase (JAK) Inhibitors in the Treatment of Rheumatoid Arthritis
Disease Control in Rheumatoid Arthritis with JAK Inhibitors
DOI:
https://doi.org/10.69750/dmls.01.04.039Keywords:
Rheumatoid Arthritis, JAK Inhibitors, Long-term Safety, Efficacy, Disease Activity, Adverse EventsAbstract
Background: Janus kinase (JAK) inhibitors are a new class of drugs for the treatment of rheumatoid arthritis (RA); however, the long-term consequences of using these drugs are still not well understood.
Objective: The primary objective of this research was to examine the effectiveness and safety of JAK inhibitors for the management of rheumatoid arthritis (RA) patients.
Methodology: Clinical raw data of 150 RA patients receiving JAK inhibitors was collected in different tertiary care hospitals in Lahore, Pakistan from March 2022 to June 2023. till were conducted. The anti-inflammatory effect was evaluated by the Disease Activity Score in 28 joints (DAS28) and the safety profile through adverse events, laboratory markers, and patients self-reported outcomes. The SPSS version 27 applied for raw data analysis which used the paired t-tests and multiple regression models to establish the factors that determine favorable outcomes and complications.
Results: JAK inhibitors also reduced the DAS28 scores from baseline to 24 months by a mean of 3. 2 ± 1. 1 (p<0. 001). The findings stated that 12 percent of the patients at baseline and 45 percent of the patients at 24 months had achieved remission. The reported side effects were infections, 25%; gastrointestinal problems, 18%; and abnormal liver function tests, 10%. Severe adverse reactions were noted in 5% of the patients and no new safety issues were observed over the course of the treatment.
Conclusion: JAK inhibitors have been shown to be useful in decreasing the activity of RA for the long-term use with reasonable side effects. The results provided evidence that JAK inhibitors were best treatment of rheumatoid arthritis (RA) but for best efficacy results closely monitoring and specific approach should be applied.
Downloads
References
Iwata S, Tanaka Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2016;12(10):1047-57. doi:10.1080/1744666X.2016.1189826
Weng C, Xue L, Wang Q, Lu W, Xu J, Liu Z. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X21999564. doi:10.1177/1759720X21999564
Martinez-Molina C, Gich I, Diaz-Torné C, Park HS, Feliu A, Vidal S, et al. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Sci Rep. 2024;14(1):172. doi:10.1038/s41598-023-50379-8
Liao X, Huo W, Zeng W, Qin F, Dong F, Wei W, et al. Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for rheumatoid arthritis: a single-center randomized trial. Adv Rheumatol. 2023;63(1):50. doi:10.1186/s42358-023-00331-1
Venetsanopoulou AI, Voulgari PV, Drosos AA. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Rev Clin Immunol. 2022;18(5):485-93. doi:10.1080/1744666X.2022.2064275
Langbour C, Rene J, Goupille P, Carvajal Alegria G. Efficacy of Janus kinase inhibitors in rheumatoid arthritis. Inflamm Res. 2023;72(5):1121-32. doi:10.1007/s00011-023-01717-z
Farnos C, Barbier V, Doussiere M, Deprez V, Hamidou Y, Bruy PA, et al. Therapeutic maintenance of Janus kinase inhibitors in real life for rheumatoid arthritis: retrospective study. J Clin Med. 2024;13(16). doi:10.3390/jcm13164608
Lanzillotta M, Boffini N, Barone E, Cincinelli G, Gerardi MC, Luciano N, et al. Safety of Janus kinase inhibitors: a real-world multicenter retrospective cohort study. J Rheumatol. 2023;50(12):1581-6. doi:10.3899/jrheum.2023-0145
Núñez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases. Drugs. 2023;83(4):299-314. doi:10.1007/s40265-023-01840-5
Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024;20(2):101-15. doi:10.1038/s41584-023-01062-9
Calvo-Garcia A, Ramírez Herráiz E, Llorente Cubas IM, Varas De Dios B, Benedí González J, Morell Baladrón A, et al. Real-world effectiveness, persistence, adherence, and safety of baricitinib: long-term study. J Clin Med. 2024;13(9). doi:10.3390/jcm13092517
Nash P, Lim I, Marabani M. Comparison of Janus kinase inhibitor safety in rheumatoid arthritis. Int J Rheum Dis. 2021;24(S1):3-14. doi:10.1111/1756-185X.14127
Wang F, Tang X, Zhu M, Mao H, Wan H, Luo F. Efficacy and safety of JAK inhibitors for rheumatoid arthritis: meta-analysis. J Clin Med. 2022;11(15). doi:10.3390/jcm11154459
Li S, Li F, Mao N, Wang J, Xie X. Efficacy and safety of Janus kinase inhibitors in ankylosing spondylitis: systematic review and meta-analysis. Eur J Intern Med. 2022;102:47-53. doi:10.1016/j.ejim.2022.04.007
Harkins P, Burke E, Swales C, Silman A, Conway R. Are JAK inhibitors safe and effective in psoriatic arthritis? Int J Rheum Dis. 2023;26(1):31-42. doi:10.1111/1756-185X.14447
Hayashi S, Nakano N, Tsubosaka M, Kamenaga T, Kuroda Y, Matsumoto T, et al. Real-world study comparing the efficacy of Janus kinase inhibitors in difficult-to-treat rheumatoid arthritis. Clin Rheumatol. 2024. doi:10.1007/s10067-024-07117-w
Wei Q, Wang H, Zhao J, Luo Z, Wang C, Zhu C, et al. Cardiovascular safety of Janus kinase inhibitors in rheumatoid arthritis: systematic review and network meta-analysis. Front Pharmacol. 2023;14. doi:10.3389/fphar.2023.1237234
Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y-W, Chen Y-H, et al. Safety and effectiveness of peficitinib: long-term extension study. Rheumatol Ther. 2021;8(1):425-42. doi:10.1007/s40744-021-00280-5
Scheepers L, Yang Y, Chen YL, Jones G. Persistence of JAK inhibitors in rheumatoid arthritis: Australia-wide study. Semin Arthritis Rheum. 2024;64:152314. doi:10.1016/j.semarthrit.2023.152314
Liu L, Yan Y-D, Shi F-H, Lin H-W, Gu Z-C, Li J. Comparative efficacy and safety of JAK inhibitors as monotherapy and combined with MTX: systematic review and meta-analysis. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.977265
Dyab NE, Al Hurh AA, Knifaty AM, Mahdy EW. Efficacy of JAK inhibitors with methotrexate for rheumatoid arthritis: systematic review and meta-analysis. Sch Bull. 2024;10(7):174-85.
Downloads
PlumX Metrics
Published
Issue
Section
How to Cite
